Ad
related to: epoetin alfa eprex- RYTELO™ MOA
View the RYTELO™
Mechanism of Action.
- RYTELO™ Efficacy
Learn About the RYTELO™
Efficacy -See Trial results.
- Request a Representative
Learn About a Treatment Option.
Connect With a Representative.
- RYTELO™ Patient Website
Visit Our Official Patient Site for
More Information About RYTELO™.
- RYTELO™ MOA
Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
[5] [6] They work similar to naturally occurring erythropoietin. [1] They were first approved for medical use in the United States in 1989. [5] It is on the World Health Organization's List of Essential Medicines. [7] Commercially available agents include epoetin alfa and darbepoetin alfa, and biosimilars.
Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n,-r ə-,-p ɔɪ ˈ ɛ t ɪ n,-ˈ iː t ɪ n /; [1] [2] [3] EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow.
Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin .
Methoxy polyethylene glycol-epoetin beta, sold under the brand name Mircera, is a long-acting erythropoietin receptor activator (CERA) used for the treatment of anaemia associated with chronic kidney disease. [4] It is the first approved, chemically modified erythropoiesis-stimulating agent (ESA). [citation needed]
After successful tests on patients undergoing dialysis, Epoetin alfa, marketed by Amgen under the trade name Epogen starting in 1989, became a financial success, generating a billion-dollar market for Amgen and other companies that had developed their own versions of erythropoietin, though Goldwasser would say that "the enormous clinical ...
Continuous erythropoietin receptor activator; D. Darbepoetin alfa; E. Epoetin alfa; Epoetin beta; M. Methoxy polyethylene glycol-epoetin beta
epoetin alfa-epbx/Retacrit: epoetin alfa/Procrit June 2018 [152] [153] pegfilgrastim-jmdb/Fulphila: pegfilgrastim/Neulasta July 2018 [154] filgrastim-aafi/Nivestym: filgrastim/Neupogen October 2018 [155] adalimumab-adaz/Hyrimoz: adalimumab/Humira November 2018 [156] pegfilgrastim-cbqv/Udenyca: pegfilgrastim/Neulasta November 2018 [157 ...
Ad
related to: epoetin alfa eprex